Genprex

Category: Press Releases

Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020

Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes

Read More

Genprex CEO Participates in a Second-Round Live Interview on “The Big Biz Show”

Genprex’s CEO participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.

Read More

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex

Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials

Read More

Genprex Added to Russell 3000® Index

Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution.

Read More

Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

Company executes on corporate communication strategy and advances drug branding initiatives

Read More

Genprex CEO to Interview Live on “The Big Biz Show”

Rodney Varner will be participating in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show, on Thursday, June 25.

Read More

Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development

Expansion enables full commercial scale plasmid DNA manufacturing capabilities

Read More

Genprex Scheduled to Join Russell 3000® Index

Genprex is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26.

Read More

Genprex to Present at the MoneyShow June Virtual Event

Mr. Varner will deliver an overview of the Company and provide updates on its product pipeline.

Read More

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More